Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mesalamine vs placebo Clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.74 [0.44, 1.24] | 1 study · 62 participants | Low |
Mesalamine vs placebo Histological response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.86 [0.5, 1.47] | 1 study · 62 participants | Low |
Mesalamine vs placebo Adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.26 [0.84, 1.88] | 1 study · 62 participants | Low |
Mesalamine vs placebo Withdrawals due to adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 5.92 [0.7, 49.9] | 1 study · 62 participants | Low |
Mesalamine vs placebo Serious adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 4.44 [0.49, 40.29] | 1 study · 62 participants | Low |
Mesalazine vs mesalazine + cholestyramine Clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.74 [0.5, 1.08] | 1 study · 23 participants | Very low |
Mesalazine vs mesalazine + cholestyramine Adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.22 [0.01, 4.07] | 1 study · 23 participants | Very low |
Prednisolone vs placebo Clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 4.89 [0.35, 68.83] | 1 study · 11 participants | Very low |
Probiotics vs placebo Clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 2.29 [0.32, 16.13] | 1 study · 29 participants | Very low |
Bismuth subsalicylate vs placebo Histological response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 10.8 [0.75, 155.93] | 1 study · 9 participants | Very low |
Probiotics vs placebo Adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.57 [0.22, 1.5] | 1 study · 29 participants | Very low |
Budesonide vs placebo Clinical response sensitivity analysis excluding Miehlke 2014 · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 4.56 [2.43, 8.55] | 3 studies · 94 participants | Low |
Budesonide vs placebo Histological response sensitivity analysis excluding Miehlke 2014 · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 4.15 [2.25, 7.66] | 3 studies · 94 participants | Low |
Budesonide vs placebo Maintenance of clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 3.3 [2.13, 5.09] | 3 studies · 172 participants | Low |
Budesonide vs placebo Maintenance of histological response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 3.17 [1.44, 6.95] | 2 studies · 80 participants | Very low |
Budesonide vs placebo Adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.18 [0.92, 1.51] | 5 studies · 290 participants | Low |
Budesonide vs placebo Withdrawals due to adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.97 [0.43, 2.17] | 5 studies · 290 participants | Very low |
Budesonide vs placebo Serious adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.11 [0.15, 8.01] | 4 studies · 175 participants | Very low |
Boswellia serrata extract vs placebo Clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.64 [0.6, 4.49] | 1 study · 31 participants | Low |
Boswellia serrata extract vs placebo Adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.88 [0.19, 18.6] | 1 study · 31 participants | Low |
Boswellia serrata extract vs placebo Withdrawals due to adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 2.82 [0.12, 64.39] | 1 study · 31 participants | Low |
Budesonide vs mesalazine Clinical response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.82 [1.13, 2.93] | 1 study · 55 participants | Low |
Budesonide vs mesalazine Histological response · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 1.97 [1.24, 3.13] | 1 study · 55 participants | Low |
Budesonide vs mesalazine Adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.69 [0.43, 1.1] | 1 study · 55 participants | Low |
Budesonide vs mesalazine Withdrawals due to adverse events · Patients with collagenous colitis Interventions for treating collagenous colitis (2017) · Cochrane | RR 0.09 [0.01, 1.65] | 1 study · 55 participants | Low |
Summary of findings table: chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Overall survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.75 [0.68, 0.84] | 11 studies · 1347 participants | High |
Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC Overall survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.81 [0.71, 0.92] | 5 studies · 750 participants | High |
Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.58 [0.28, 1.18] | 2 studies · 540 participants | Very low |
Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC Toxicity · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 3 studies · 972 participants | Very low |
Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC Quality of life · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 4 studies · 1129 participants | Very low |
Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Overall survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.71 [0.54, 0.94] | 4 studies · 769 participants | Moderate |
Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.51 [0.29, 0.9] | 3 studies · 677 participants | Low |
Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Toxicity · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 4 studies · 1638 participants | Very low |
Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Quality of life · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 4 studies · 1638 participants | Very low |
Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention alone Overall survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.73 [0.63, 0.85] | 5 studies · 358 participants | Moderate |
Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention alone Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table: chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.64 [0.45, 0.92] | 5 studies · 883 participants | Moderate |
Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention alone Toxicity · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 4 studies · 1638 participants | Very low |
Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention alone Quality of life · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 450 participants | Very low |
Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention alone Overall survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.75 [0.63, 0.9] | 6 studies · 989 participants | High |
Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention alone Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.64 [0.45, 0.92] | 5 studies · 883 participants | Moderate |
Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention alone Toxicity · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 6 studies · 3020 participants | Very low |
Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention alone Quality of life · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 4 studies · 2054 participants | Very low |
Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Overall survival · palliative participants with AC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.66 [0.54, 0.81] | 5 studies · 538 participants | High |
Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Progression‐free survival · palliative participants with AC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.62 [0.38, 1] | 4 studies · 713 participants | Very low |
Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Toxicity · palliative participants with AC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 5 studies · 2676 participants | Very low |
Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Quality of life · palliative participants with AC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 4 studies · 1772 participants | Very low |
Summary of findings table: chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Toxicity · palliative participants with esophageal and GE‐junction carcinoma Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | no estimate extracted | 9 studies · 3296 participants | Very low |
Summary of findings table (subcomparison 6): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Overall survival · palliative participants with SCC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.76 [0.65, 0.9] | 4 studies · 268 participants | High |
Summary of findings table (subcomparison 6): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention alone Progression‐free survival · palliative participants with SCC of the esophagus Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer (2017) · Cochrane | HR 0.72 [0.55, 0.96] | 2 studies · 168 participants | Very low |